How many years can you live taking giritinib?

There is no definite answer to how many years one can live on giritinib, because it is affected by many factors, including the patient's constitution, severity of the disease, response to the drug, etc. However, through data from clinical trials and real-world applications, we can have a certain understanding of the efficacy of giritinib.

First, giritinib is a potent, oral, selectiveFLT3 inhibitor for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who carry FLT3 mutations. In clinical trials, giritinib showed significant efficacy. For example, in a phase 3 clinical trial, adult patients with relapsed or refractory FLT3-mutated AML were randomly assigned to receive giritinib or salvage chemotherapy. The results showed that the median overall survival time of the giritinib group was significantly longer than that of the chemotherapy group (9.3 months vs. 5.6 months). This suggests that, for these patients, giritinib can significantly prolong survival.

However, this does not mean that every patient can achieve such results. The patient's survival period is also affected by various factors such as individual differences, severity of the disease, and whether timely treatment is received. Therefore, a firm survival prediction cannot simply be given.

In addition, although giritinib can prolong survival, it may also cause some adverse reactions, such as febrile neutropenia, anemia, thrombocytopenia, etc. Therefore, when using giritinib, it is necessary to pay close attention to the patient's response and adjust the treatment plan in a timely manner to ensure the patient's safety and efficacy.